Pioglitazone (peroxisome proliferator-activated receptor agonists) and metformin (insulin-sensitizing agent) as antidiabetic drugs in a combined therapy might have a synergistic protective effect on non-alcoholic fatty liver disease (NAFLD) by improving hepatic lipid profiles in HFD-induced mice [25] and newly diagnosed T2DM patients [26], indicating that GF5000 could be a potential drug candidate for T2DM and NALFD. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.